HudisC.A.: Trastuzumab: mechanism of action and use in clinical practice.N Engl J Med, 357: 39–51, 2007.
2.
MayerL., NohriaA., MillerK., RugoH., CareyL., RyabinN., GelmanR.S., WinerE., BursteinH.: Cardiovascular safety of adjuvant bevacizumab for breast cancer. Abstr. 571, Proc Am Soc Clin Oncol, 2010.
3.
LevineA.M., TulpuleA., EspinaB., SherrodA., BoswellW.D., LiebermanR.D., NathwaniB.N., WellesL.: Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's Lymphoma: results of therapy and correlates of response.J Clin Oncol, 13: 2662–2670, 2004.
4.
BuzdarA.U., LeghaS.S., HortobagyiG.N., YapH.Y., WisemanC.L., DistefanoA., SchellF.C., BarnesB.C., CamposL.T., BlumenscheinG.R.: Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens.Cancer, 47: 2798–2802, 1981.
5.
GennariA., BruzziP., OrlandiniC., SalvadoriB., DonatiS., LanducciE., GuarneriV., RondiniM., RicciS., ConteP.: Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.Br J Cancer, 90: 962–967, 2004.
van DalenE.C., MichielsE.M., CaronH.N., KremerL.C.: Different anthracycline derivates for reducing cardiotoxicity in cancer patients.Cochrane Database Syst Rev, 4: CD005006, 2010.
8.
TheodoulouM., BatistG., CamposS., WinerE., WellesL., HudisC.: Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.Clin Breast Cancer, 9: 101–107, 2009.
9.
CortesJ., Di CosimoS., ClimentM.A., Cortés-FunesH., LluchA., GascónP., MayordomoJ.I., GilM., BenavidesM., CireraL., OjedaB., RodríguezC.A., TrigoJ.M., VazquezJ., RegueiroP., DoradoJ.F., BaselgaJ.: Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.Clin Cancer Res, 15: 307–314, 2009.
